Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.

ABSTRACT:

Background

Patients with pulmonary arterial hypertension (PAH) and additional cardiac or pulmonary comorbidities have a poor prognosis and are frequently excluded from clinical trials. The purpose of this study was to evaluate outcomes of patients with pulmonary hypertension (PH) secondary to a range of World Symposium on PH (WSPH) groups treated with inhaled treprostinil (iTRE) in a real-world setting.

Methods

Patients with PH who were started on treatment with iTRE at Duke University were classified by WSPH Group and included patients with Groups 1, 2, 3, combined Groups 2 and 3 (PH in the setting of left heart failure and chronic lung disease), Group 4, and Group 5 PH. Time to disease worsening, a composite of death, lung transplantation, or transition to intravenous pros

SUBMITTER: Swaminathan AC 

PROVIDER: S-EPMC11935515 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature